background: Phthalates are known to have estrogenic effects in cell models and experimental animals. However, the evidence regarding the effects of phthalates on human reproduction is still limited. We conducted a case-control study to determine whether estrogendependent diseases are associated with phthalate exposure and how the glutathione S-transferase M1 (GSTM1; a major detoxification enzyme) genotype modulates the risk.
Introduction
The etiologies of some estrogen-dependent gynecologic conditions, such as endometriosis (EN), adenomyosis (AD) and leiomyomas (LEIs), are still unclear. EN is defined as the presence of endometrial tissue outside the uterine cavity, whereas AD refers to the condition when endometrial tissues invade the myometrium with smooth muscle hyperplasia (Devlieger et al., 2003; Bulun, 2009) . LEIs, also known as fibroids, are defined as benign tumors of smooth muscle (Al-Hendy and Salama, 2006) in the uterus. EN, AD and LEIs are common gynecologic disorders presented by prolonged or heavy menstrual bleeding, pelvic pain and infertility. The prevalence of EN has been reported to be 2-22% in women of childbearing age, whereas AD and LEIs have a prevalence of 20 -35% in the infertility clinic and 20-25% in premenopausal women, respectively, and varies by ethnic groups (Devlieger et al., 2003; Guo, 2005; Al-Hendy and Salama, 2006) . Susceptibility to these estrogen-dependent gynecologic conditions depends on complex interactions between immunologic, hormonal, environmental and genetic factors (Giudice and Kao, 2004) .
Previous studies have revealed that some extensively used plasticizers, known as phthalates, are possibly associated with EN (Cobellis et al., 2003; Reddy et al., 2006a, b) . Phthalates are added to plastics to make them soft and flexible, to cosmetics as a vehicle for fragrances and to many other daily products, such as building materials, children's toys and medical devices (Schettler, 2006) . Recent reports have shown that phthalates are widely added in considerable amounts (up to 5%) to cosmetics and personal care products, and that they raise the levels of exposure to urinary phthalate monoesters rapidly when these products are used daily (Houlihan et al., 2002; Duty et al., 2005) , particularly in women.
Phthalates are estrogenic and anti-androgenic endocrine disruptors that may prolong menstrual cycles and increase the proportion of premature menopause in animal models (Moore, 2000; Ma et al., 2006) . Toxicological evidence has shown that some phthalates, such as butyl benzyl phthalate (BBzP), di-n-butyl phthalate (DnBP) and di-(2-ethylhexyl) phthalate (DEHP), may alter or mimic estradiol (E 2 ) in vivo and in vitro (Harris et al., 1997; Okubo et al., 2003; Jin et al., 2008) . However, whether phthalate exposure results in adverse effects on the human reproductive system is largely unknown.
Several studies have examined a relationship between estrogendependent gynecologic conditions and genetic polymorphisms of human detoxification enzymes, including N-acetyltransferase 2, glutathione S-transferases (GST) M1 and T1 (Baranova et al., 1997 (Baranova et al., , 1999 and cytochrome P450 (CYP) 1A1 (Juo et al., 2006) . Previous studies have suggested that the GSTM1 null mutation is associated with EN in French (Baranova et al., 1997 (Baranova et al., , 1999 , Greek (Arvanitis et al., 2003) and Indian (Babu et al., 2005) populations. However, other studies have concluded that neither GSTM1 mutations nor CYP 1A1 is linked to EN in Korean (Hur et al., 2005) , Taiwanese (Juo et al., 2006) and English (Hadfield et al., 2001) populations. The inconsistent results could be due to small sample size or different genetic backgrounds between ethnic groups, and therefore whether genetic variability acts as a critical factor in EN is still under debate (Guo, 2005) . Furthermore, for complex gynecologic conditions, such as EN and AD, it is likely that gene-environmental interactions are more important and relevant than genetics alone.
The present study was aimed to explore the possible interaction between phthalates and GSTM1 on estrogen-dependent gynecologic conditions, including AD, EN and LEIs. We first examined the relationship between gynecologic conditions and phthalate exposure using urinary phthalate monoesters as the exposure biomarkers, and determined whether GSTM1 polymorphisms can modify individual risk for such conditions. The results of this study will also help us further understand the possible adverse effects of phthalates and provide hints on the role of GST enzymes in phthalate detoxification.
Materials and Methods

Subject recruitment
We recruited patients who had undergone laparotomy in the Department of Obstetrics and Gynecology of Kaohsiung Medical University Hospital (KMUH) in Taiwan between 2005 and 2007, and had pathologic confirmation of EN, AD and LEIs. The diagnoses of EN and AD were based on the pathologic results of the presence of endometrial tissue outside the uterine cavity and within the myometrium with smooth muscle hyperplasia, respectively. The diagnosis of LEIs was based on the pathologic finding of a benign tumor within the uterine smooth muscle. In this study, 28 cases of EN, 16 cases of AD and 36 cases of LEIs were included.
Women who underwent laparotomy for other clinical reasons and did not have EN, AD or LEIs, as confirmed by pathology, served as the control group. The laparotomy was performed to exclude subjects with pelvic masses, such as uterine and ovarian tumors. Women who had been previously diagnosed with these estrogen-dependent gynecologic conditions were also excluded. All cases and controls were of Chinese descent. This protocol was approved by the Institutional Review Board of KMUH and informed consent was obtained from the participants before the study.
Demographic characteristics
The demographic data of each subject were obtained from an interviewed questionnaire during the recruitment process. The recorded characteristics included age, body mass index (BMI), education, age of menarche, duration of menstrual cycle, history of abnormal uterine bleeding, parity, hormone therapy, intrauterine device (IUD) use, oral contraceptive use, caffeinated drink consumption, cigarette smoking, alcohol consumption, a family history of gynecologic diseases and dietary habits.
Blood and urine collection
Blood samples were collected in tubes with EDTA and stored at 48C for 20 -30 min. Blood samples were centrifuged at 1620 g for 15 min and lymphocytes obtained from the blood sample (8 ml) were collected and analyzed for the GSTM1 genotype. A 20 -30 ml urine sample was collected in a 250 ml glass vessel and immediately transferred into a 12 ml amber glass bottle for phthalate monoesters and creatinine analysis. To prevent possible contamination of the urine samples, all the glassware had been washed in methanol, acetonitrile and acetone, and then was sealed with aluminum foil before sample collection.
Genotype determination
The GSTM1 genotype was determined by polymerase chain reaction (PCR) based on a method described previously (Shinka et al., 1998) . PCR, containing 100 ng of genomic DNA, was incubated at 948C for 5 min and subjected to 35 cycles at 948C for 30 s, 588C for 60 s, 728C for 60 s and a final extension at 728C for 10 min. The presence of the GSTM1 allele was shown as a fragment of 215 bp on 2% agarose gel. The primers used were 5 0 -GAACTCCCTGAAAAGCTAAAGC-3 0 and 5 0 -GTTGGGCTCAAATATACGGTGG-3 0 .
Urinary phthalate monoesters analysis
Standards of phthalate metabolites, including mono-methyl phthalate (MMP), mono-ethyl phthalate (MEP), mono-n-butyl phthalate (MnBP), mono-benzyl phthalate (MBzP), mono-(2-ethylhexyl) phthalate (MEHP), mono-(2-ethyl-5-oxo-hexyl) phthalate (5oxo-MEHP) and mono-(2-ethyl-5-hydroxyhexyl) phthalate (5OH-MEHP), and their corresponding 13 C 4 -labeled compounds were purchased from Cambridge Isotope Laboratories (Andover, MA, USA). Formic acid (FA), acetic acid and b-glucuronidase (Helix pomatia) were purchased from Sigma-Aldrich (St Louis, MO, USA). Methanol (HPLC grade) was purchased from Merck (Darmstadt, Germany). Deionized water was acquired from a Millipore system (Milford, MA, USA). Seven urinary phthalate monoesters were analyzed using on-line solid-phase extraction (SPE) coupled with Phthalate and GSTM1 polymorphism in estrogen-dependent diseases liquid chromatography/electrospray ionization tandem mass spectrometry (LC/ESI-MS/MS), which was adapted from a previous study Huang et al., 2007) . Briefly, 1 ml aliquots of the sample containing 750 ml urine, 50 ml of 2000 ppb 13 C 4 -labeled phthalate monoesters as internal standards, 200 ml of 100 mM ammonium acetate buffer (pH 6.5) and 10 ml of b-glucuronidase were incubated at 378C for 90 min for deconjugation. The deconjugation reaction was stopped by the addition of 20% acetic acid/can (50 ml). The mixture was passed through a 0.2 mm PVDF membrane filter (MSF-3; Advantec MFS, Inc., Pleasanton, CA, USA) and stored at 48C prior to loading onto the analytical system. Then, the urine mixture was loaded onto the on-line SPE cartridge (C18 trap cartridge, 2.0 Â 55 mm, 3 mm; Merck) and washed with 2% FA/H 2 O at a flow rate of 600 ml/min for 10 min before the switching valves (6-ports; Valco Europe, Schenkon, Switzerland) were triggered to start the LC gradient and initiate chromatography on the Chromolith column Flash RP-18e column (4.6 Â 50 mm; Merck). The gradient program was started with a mobile phase from 0.1% FA/H 2 O at a flow rate of 600 ml/min to 100% MeOH in 10 min. The LC eluent was split into a 1:20 ratio before entering the mass spectrometer (API365 triple quadrupole; PE Sciex, Throhill, Ontario, Canada). After gradient analysis was completed, the Chromolith column was washed with MeOH for 5 min and re-equilibrated with 2% FA/H 2 O for 1 min before the next injection. The precursor to product ion transitions of seven phthalate monoesters and their corresponding 13 C 4 -labeled compounds were the same as reported in a previous study (Kato et al., 2005) . The dynamic concentration ranges of the calibration curves for MMP, MEP, MBzP, 5OH-MEHP and 5oxo-MEHP were 0.67 -1300 ng/ml, whereas the dynamic concentration ranges of the calibration curves for MnBP and MEHP were 0.67 -670 ng/ml. The intra-day variations of these phthalate monoesters in urine at three different concentrations (25%, 50% and 75%) within the dynamic range of the individual substance were all ,10% with intra-day recoveries at 100 + 20%. The detection limits of MMP, MEP, MnBP, MBzP, MEHP, 5OH-MEHP and 5oxo-MEHP were 3.4, 2.2, 1.6, 0.99, 0.55, 0.23 and 0.26 ng/ml, respectively. The accuracy of the analytical approach was tested against two reference urine samples with different known phthalate monoester concentrations. The samples were received from the laboratory inter-comparison program (www.g-equas.de) in 2006. The relative errors of the five urinary monoesters (MnBP, MBzP, MEHP, 5OH-MEHP and 5oxo-MEHP) were ,16%, whereas MMP and MEP were not included in the reference sample.
Statistical analysis
The Kruskal -Wallis and the Wilcoxon rank sum tests were used to evaluate the difference in demographic data among all groups and between groups, respectively. We also used the Wilcoxon rank sum test to assess the difference in phthalate exposure between cases and controls. All phthalate metabolite measurements were log transformed to approximate normal distribution. As 5OH-MEHP and 5oxo-MEHP are both the further metabolites of MEHP, we calculated the sum of MEHP (SMEHP) by combining the levels of 5oxo-MEHP, 5OH-MEHP and MEHP measurements to evaluate the total exposure of DEHP.
Deviation from the Hardy -Weinberg equilibrium (HWE) was examined using a x 2 test. Genotypic effects were evaluated for three estrogendependent gynecologic conditions. We also categorized the subjects into two groups by the median levels of phthalate metabolites to evaluate the joint effects of GSTM1 polymorphism. Then, we evaluated the odds ratio (OR) of individual case groups carrying the GSTM1 null genotype using logistic regression. We used logistic regression to assess whether there was a significant risk increase between the case group with higher phthalate exposure and the control group. Potential covariance was adjusted in these two simple models. Further, stepwise backward logistic regression analysis was carried out to adjust for significant covariates, including age and BMI. We used the control group as a reference in the logistic model and a cut-off point of P , 0.2 was applied as the criterion for backward variable selection. In addition, we put only the most sensitive exposure variable (urinary phthalate metabolites) into the final models to avoid confounding co-linearity. In order to assess the interaction of phthalate exposure and GSTM1 polymorphism, four groups are categorized as follows: those with GSTM1 and below-median SMEHP exposure, those with GSTM1 and above-median SMEHP exposure, those with GSTM1 null type and belowmedian SMEHP exposure, and those with GSTM1 null type and abovemedian SMEHP exposure. We used two dummy variables for evaluation of interaction. Dummy variable 1 (DV1): the presence and absence of GSTM1 genotype in our subjects is coded as '0' and '1', respectively. Dummy variable 2 (DV2): the exposure level of sum (MEHP) lower and higher than the median in our subjects is coded as '0' and '1', respectively. Then, we used DV1 Â DV2 as an interaction term in the model. The level of statistical significance was set at 0.05 for all analyses. All analyses were performed using SAS 9.0 software.
Results
Demographic characteristics of the study participants
The demographic characteristics of the controls and patients with EN, AD or LEIs are shown (Table I ). There was a significant difference in age, using the Wilcoxon rank sum test, between the AD and the LEI groups and the control group, but not the EN group. However, the EN group had a significantly lower BMI (21.5 + 2.9 kg/m 2 ) than the controls (23.9 + 4.8 kg/m 2 ). No significant differences in menstrual and medical histories, such as age of menarche, abnormal uterine bleeding, menstrual cycle, hormone therapy, IUD use and oral contraceptive use, and lifestyles, such as caffeinated drink consumption, cigarette smoking and alcohol consumption, were found among the control and disease groups.
Levels of phthalate monoesters
The distribution of seven urinary phthalate monoesters (creatinineadjusted and non-adjusted) among the disease and control groups is shown in Table II . Among the three disease groups, the most obvious difference in urinary phthalate monoesters when compared with controls was for the LEI group. The creatinine-adjusted (mg/g-c) levels of MMP (65.8 mg/g-c), MEHP (6.0 mg/g-c) and SMEHP (52.1 mg/g-c) in the LEI patients were significantly higher than controls (P , 0.05). For the EN group, we found increased median levels of all phthalate metabolites, except for MEP, but significant differences was found in MnBP (94.1 mg/g-c) and 5oxo-MEHP (19.0 mg/g-c), and SMEHP (42.4 mg/g-c) reached a marginal significance (P , 0.1). The difference in urinary phthalate monoester levels was least evident for the AD group.
ORs for estrogen-dependent gynecologic conditions with different GSTM1 genotypes
The frequencies and crude-and adjusted OR of the GSTM1 polymorphisms among all groups are presented in Table III . Genotype of GSTM1 was in HWE in both cases and controls. The frequencies of GSTM1 null type in control, EN, AD and LEIs were 34.5%, 42.9%, 68.7% and 47.2%, respectively. Subjects with the GSTM1 null-type had higher crude OR for AD relative to those with wild-type (OR ¼ 4.89; 95% CI, 1.31-18.3). After adjustment for age, we found a small increased risk for subjects with the GSTM1 null type in the AD group (OR ¼ 5.37; 95% CI, 1.25 -23.0). The OR for the GSTM1 null type in the AD group was significantly higher than in the control Phthalate and GSTM1 polymorphism in estrogen-dependent diseases group. However, we did not find any significant ORs for GSTM1 genotypes in the EN and LEI groups, even after adjustment for BMI and age, respectively.
ORs for estrogen-dependent gynecologic conditions with different phthalates exposure
The crude and adjusted ORs of case status by above-median phthalate exposure are shown in Table IV 
Gene-environmental interaction on estrogen-dependent gynecologic conditions
The ORs for GSTM1 polymorphisms and urinary phthalate monoesters in the disease group using stepwise backward logistic regression are shown in Table V . In the EN group, the OR for BMI was 0.88 (95% CI, 0.75 -1.04), whereas the OR for the urinary log MnBP was 2.92 (95% CI, 0.92 -9.2), which only show marginal significant increase in risk. In the AD group, the OR was 1.13 (95% CI, 1.02 -1.25) for age and 5.30 (95% CI, 1.22 -23.1) for GSTM1, showing that being elderly or carrying the GSTM1 null type represents a significantly increased risk for AD. For the LEI group, age and the urinary level of SMEHP were associated with an increased risk as the ORs for age and SMEHP were 1.08 (95% CI, 1.01 -1.16) and 2.64 (95% CI, 0.89 -7.80), respectively. We found a significant joint effect of phthalates exposure and GSTM1 null type on AD and LEIs (Fig. 1) . When compared with those with GSTM1 wild-type and low urinary level of SMEHP, subjects who carried the GSTM1 null type with a high urinary level of SMEHP had a significantly increased risk for AD (crude OR ¼ 8.67; 95% CI, 1.34 -56.3, P trend ¼ 0.011) and LEIs (crude OR ¼ 5.57; 95% CI, 1.13 -27.5, P trend ¼ 0.037). After adjustment for age, the risk became even more evident as the OR increased to 10.4 (95% CI, 1.26 -85.0) for AD and 5.93 (95% CI, 1.10 -31.9) for LEIs. For interaction analysis, we found no significant interaction between GSTM1 deletion and phthalate exposure for AD (OR ¼ 1.7; 95% CI, 0.09-31.2), LEI (OR ¼ 0.6; 95% CI, 0.06 -5.3) or EN (OR ¼ 3.5; 95% CI, 0.31 -38.5).
Discussion
This is the first study to explore the gene-environmental interaction of phthalates exposure and GSTM1 polymorphisms on EN, AD and LEI. We found that urinary SMEHP was associated with an increased risk of AD and LEI after adjustment of GSTM1 genotype. No association was observed between urinary phthalate metabolites and GSTM1 polymorphisms in EN. Previous studies have reported that some phthalates, such as DnBP, BBzP and DEHP, are associated with EN (Cobellis et al., 2003; Reddy et al., 2006a, b Demographic factors were adjusted in the logistic regression models. BMI was adjusted for EN, whereas age was adjusted for AD and LEI, respectively. exposure due to less contamination during the process of sampling and analysis (Silva et al., 2004; Kato et al., 2005) . Determining urinary monoesters and oxidative monoesters of phthalates in our subjects provided the reliable exposure data. Besides, we recruited laparotomy-confirmed controls, which reduced the selection bias from the potential cases in the non-laparotomy-confirmed controls. A few of our controls had gynecologic conditions such as endometrial polyps and ovarian cysts. Although we found no evidence in the literature that phthalate exposures are associated with these diseases, other estrogenic compounds such as bisphenol A (BPA) have been associated with them (Vandenberg et al., 2007) . It is thus plausible that phthalates, which are also estrogenic, might be associated with some of the gynecologic conditions in our control group, despite a paucity of research in the literature. If this was true, the phthalate exposures in our control group would be elevated leading toward the null hypotheses of no association. It is possibly the reason why we did not observe any correlation between phthalate exposure and GSTM1 genotype in EN, which requires a large sample size to clarify. However, the associations between phthalate exposure and GSTM1 polymorphism in AD and LEI still exist.
In the present study, we found that BMI and age are potential risk factors for EN and AD/LEI, respectively, which is consistent with previous studies (Cramer and Missmer, 2002; Vercellini et al., 2006) , whereas other demographic characteristics, such as age at We categorized our subjects into two groups according to the median levels of each urinary phthalate metabolite. Phthalate and GSTM1 polymorphism in estrogen-dependent diseases menarche and smoking, did not show statistical difference. The frequency of the GSTM1 null genotype has been reported in different ethnic groups, ranging from 21% to 77%, and conflicting conclusions have been offered in different populations. In the current study, the frequency of the GSTM1 null genotype in our controls was 34.5%, which is comparable to the Hans population (35 -63%; Rebbeck, 1997; Lin et al., 2003) . The frequency of GSTM1 null type in EN is 42.9%, which is comparable to the Indian population (39%; Babu et al., 2005) , and approximates the Hans population (51%; Ding et al., 2004) . Although our results of GSTM1 polymorphisms in EN and controls were different from Japanese and Korean studies (Morizane et al., 2004; Hur et al., 2005) , our results are in agreement with most previous studies reporting no association between GSTM1 and EN. Our data reveal that the risk of SMEHP exposure in AD and LEI with the GSTM1 null genotype was significantly increased. DEHP, the parent compound of MEHP, MEHHP, MEOHP and other phthalates, has estrogenic effects in vivo and in vitro studies (Harris et al., 1997; Jin et al., 2008) , although a few studies have conflicting findings (Hong et al., 2005) . No human studies have focused on the interaction between phthalates exposure and GSTM1 genotyping in women with AD and LEI. The effects of other estrogenic endocrine disruptors on AD may provide some clues. One study showed that low-dose diethylstilbestrol exposure may affect the development of AD in female mice (Huseby and Thurlow, 1982) . Another study reported that long-term exposure to BPA, which has similar estrogenic activity to phthalates, can cause AD in female CD-1 mice (Newbold et al., 2007) . Therefore, we suggest that both GSTM1 null and phthalate exposure are associated with AD and LEI, but our study lacked power to test for interactions. The potential effects from phthalates exposure modified by estrogen-receptorrelated genotypes or other enzymes on the estrogen-dependent gynecologic diseases are worthy of future investigation. Larger studies to investigate potential interaction between GSTM1 null and phthalate exposure in the etiology of estrogen-dependent gynecologic conditions are warranted.
Interestingly, we also found a significant correlation between urinary MEHP and MnBP (Pearson's correlation coefficient: r ¼ 0.31, P ¼ 0.001), which is also reported in another study (Becker et al., 2009) . Low correlation between urinary MEHP and MnBP may indicate that the exposure sources of their parent compounds, DEHP and DnBP, in our subjects could partly come from similar sources. It is reported that high percentages of DEHP and DnBP exposure in humans come from food intake, possibly by contamination in the process of food preparation and leaching out from plastic containers (Schettler, 2006) . In addition, DEHP and DnBP are also used in cosmetic and personal care products Houlihan et al., 2002) . The co-exposure of DEHP and DnBP may occur as women tend to use various types of these products, such as deodorant, perfume, hair spray, nail polish etc. in their daily routine. However, lacking an integrated toxic equivalence factor of phthalates may underestimate the joint effects of total phthalates exposure and GSTM1 polymorphism in our subjects.
The present study had some limitations. First, although the small sample size may limit our interpretation, our results provide useful data for further investigation. Further, studies with a large sample size are needed. Second, other gynecologic conditions in controls may derive from estrogenic compounds, such as BPA or phthalates, which may lead toward the null result of no association. Third, we did not have age-matched controls for each estrogen-dependent gynecologic condition. Because the presenting age of women with EN, AD and LEIs was quiet different, we used laparotomy-confirmed criteria for subject recruitment. Then, we used age as a covariance in the regression models. Fourth, because phthalates are ubiquitous in our environment and consumer products, it is generally hypothesized that phthalate exposure in humans is continual and the intensity is gradually increased, especially in women (DiGangi and Norin, 2002; Houlihan et al., 2002; Duty et al., 2005) . In addition, recent studies have also reported the prenatal, post-natal and children's exposure to phthalate, and its potential effects in early gene expression during embryonic stem cell and neonates (Wolff et al., 2007; Becker et al., 2009; Engel et al., 2009; Huang et al., 2009; van Dartel et al., 2009) . However, the missing evidence of phthalate exposure during the critical period for development of measured outcomes is still a limitation of this study. Fifth, because we set 0.05 as the significant level of each statistic testing, it may produce a few false associations by multiple testing. Owing to different phthalates exposure in humans from different sources, it is helpful to identify possible exposure profiles of phthalate in human subject by multiple comparison of phthalate exposure between cases and controls. In order to validate our findings, we used stepwise backward logistic regression model to avoid the false association. Therefore, our findings still provide important information for future studies on estrogen-dependent gynecologic conditions. Figure 1 Joint effects of total MEHP exposure and GSTM1 polymorphism on adenomyosis (AD) and leiomyoma (LEI) after adjustment for age.
Low and high SMEHP groups were divided by the median concentrations of SMEHP (38.9 mg/g c). GSTM1 ( -) represents the GSTM1 null-type, whereas GSTM1 (þ) represents the GSTM1 wild-type. Asterisk indicates significant difference (P,0.05) as compared to the group of low SMEHP/ wild-genotype group. Significant trend was found for AD (P ¼ 0.011) and LEI (P ¼ 0.037), respectively.
Conclusions
We found a significantly increased risk for AD and LEI in subjects with high MEHP exposure and GSTM1 deletions. However, we did not observe any significant interaction between phthalates exposure and GSTM1 polymorphisms in EN, AD or LEI, probably limited by the sample size. We suggest that both GSTM1 null and phthalate exposure are associated with AD and LEI, but our study lacked power to test for interactions. Larger studies to investigate potential interaction between GSTM1 null and phthalate exposure in the etiology of estrogen-dependent gynecologic conditions are warranted.
